3692 — Hansoh Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- HK$95.29bn
- HK$73.03bn
- CNY10.10bn
- 86
- 24
- 96
- 83
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8,683 | 8,690 | 9,935 | 9,382 | 10,104 |
Cost of Revenue | |||||
Gross Profit | 7,945 | 7,887 | 9,065 | 8,512 | 9,073 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5,682 | 5,592 | 6,582 | 6,376 | 6,271 |
Operating Profit | 3,001 | 3,098 | 3,353 | 3,007 | 3,833 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 3,001 | 3,098 | 3,300 | 2,948 | 3,766 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2,557 | 2,569 | 2,713 | 2,584 | 3,278 |
Net Income Before Extraordinary Items | |||||
Net Income | 2,557 | 2,569 | 2,713 | 2,584 | 3,278 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 2,557 | 2,569 | 2,654 | 2,584 | 3,278 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.467 | 0.437 | 0.442 | 0.434 | 0.543 |
Dividends per Share |